Press Releases

23 Dec 2013European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Cangrelor04 Dec 2013The Medicines Company Acquires Rempex Pharmaceuticals27 Nov 2013The Medicines Company to Participate in Upcoming Investor Conference Webcasts21 Nov 2013European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Fibrocaps Hemostatic Agent20 Nov 2013Drug Designation, Patents, Milestone Payment, Quarterly Result, and Medical Study - Research Report on The Medicines Company, VIVUS, Isis, HeartWare, and Masimo12 Nov 2013FDA Grants QIDP Designation to The Medicines Company's Investigational Antibiotic Oritavancin12 Nov 2013Upcoming Conferences, Financial Results, Dividends, and Public Offerings - Research Report on Medicines Company, Isis, Ligand, Teleflex, and Tetraphase05 Nov 2013The Medicines Company to Participate in Credit Suisse Healthcare Conference30 Oct 2013The Medicines Company's EUROMAX Trial of Angiox(R) (Bivalirudin) in Heart Attack Meets All Prespecified Endpoints23 Oct 2013The Medicines Company Reports Third Quarter 2013 Financial Results09 Oct 2013First Patient Enrolled in Phase III Trial Evaluating The Medicines Company's Angiomax(R) (Bivalirudin) in Patients Undergoing Peripheral Endovascular Procedures09 Oct 2013The Medicines Company Completes Two Pharmacodynamic Trials Testing Transition of Intravenous Antiplatelet Cangrelor to Oral Ticagrelor and Prasugrel09 Oct 2013The Medicines Company and Alnylam Advance Development Candidate for ALN-PCSsc, a Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 Under Investigation for the Treatment of Hypercholesterolemia10 Sep 2013Phase 3 Data From The Medicines Company's Oritavancin Solo Trials Featured at ICAAC Conference03 Sep 2013Totality of Data From Three Phase III Trials of The Medicines Company's Intravenous Cangrelor Presented and Published13 Aug 2013The Medicines Company Prices Public Offering of Common Stock12 Aug 2013The Medicines Company Announces Proposed Public Offering of Common Stock05 Aug 2013The Medicines Company Announces Positive Phase III Trial Results for Fibrocaps; Completes ProFibrix Acquisition24 Jul 2013The Medicines Company Reports Second Quarter and First Half 2013 Financial Results02 Jul 2013The Medicines Company Announces Positive Results for Solo II Trial of Oritavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)01 Jul 2013FDA Accepts the Filing of The Medicines Company's New Drug Application for Intravenous Antiplatelet Agent Cangrelor04 Jun 2013The Medicines Company Signs Agreement to Acquire ProFibrix24 Apr 2013The Medicines Company Reports First Quarter 2013 Financial Results10 Mar 2013The Medicines Company's Intravenous Cangrelor Demonstrates 22% Reduction in Ischemic Events Compared to Oral Clopidogrel20 Feb 2013The Medicines Company Reports Fourth Quarter and Full Year 2012 Financial Results08 Feb 2013The Medicines Company and Bristol-Myers Squibb Begin Global Alliance for Recothrom(R)04 Feb 2013The Medicines Company and Alnylam Form Strategic Alliance to Develop and Commercialize RNAi Therapeutics Targeting PCSK9 for the Treatment of Hypercholesterolemia08 Jan 2013The Medicines Company Announces Positive Results in a Phase 3 Trial of Cangrelor in the Treatment of Patients Undergoing PCI07 Jan 2013The Medicines Company Completes Acquisition of Incline Therapeutics, Inc.

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com